Rebamipid: Perbedaan antara revisi

'''RebamipideRebamipid''' adalah turunan [[Asam amino|asam amino]] dari 2-(1''H'')-quinolinon yang digunakan untuk perlindungan [[Membran mukosa|mukosa]], <ref>{{Cite journal|last=Arakawa|first=T.|last2=Kobayashi|first2=K.|last3=Yoshikawa|first3=T.|last4=Tarnawski|first4=A.|date=1998|title=Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing|url=https://www.ncbi.nlm.nih.gov/pubmed/9753220|journal=Digestive Diseases and Sciences|volume=43|issue=9 Suppl|pages=5S–13S|issn=0163-2116|pmid=9753220}}</ref> penyembuhan [[Ulkus peptikum|tukak lambung]] (ulkus peptikum), dan pengobatan maag ([[Maag|gastritis)]].<ref>{{Cite journal|last=Arakawa|first=T.|last2=Watanabe|first2=T.|last3=Fukuda|first3=T.|last4=Yamasaki|first4=K.|last5=Kobayashi|first5=K.|date=1995|title=Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine|url=https://www.ncbi.nlm.nih.gov/pubmed/7587834|journal=Digestive Diseases and Sciences|volume=40|issue=11|pages=2469–2472|issn=0163-2116|pmid=7587834}}</ref> Obat ini bekerja dengan meningkatkan pertahanan mukosa, membersihkan [[Radikal bebas|radikal]] bebas,<ref>{{Cite journal|last=Takumida|first=Masaya|last2=Anniko|first2=Matti|date=2009|title=Radical scavengers for elderly patients with age-related hearing loss|url=https://www.ncbi.nlm.nih.gov/pubmed/18607930|journal=Acta Oto-Laryngologica|volume=129|issue=1|pages=36–44|doi=10.1080/00016480802008215|issn=1651-2251|pmid=18607930}}</ref> dan mengaktifkan gen penyandi [[siklooksigenase]]-2 secara sementara.<ref>{{Cite journal|last=Tarnawski|first=A. S.|last2=Chai|first2=J.|last3=Pai|first3=R.|last4=Chiou|first4=S. K.|date=2004|title=Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?|url=https://www.ncbi.nlm.nih.gov/pubmed/15104358|journal=Digestive Diseases and Sciences|volume=49|issue=2|pages=202–209|issn=0163-2116|pmid=15104358}}</ref>

RebamipideRebamipid tersedia di sejumlah negara Asia termasuk [[Jepang]] (dipasarkan sebagai '''Mucosta'''), [[Korea Selatan]], [[Republik Rakyat Tiongkok|Cina]],<ref> [https://www.drugs.com/international/rebamipide.html drugs.com] </ref> dan [[India]] (dipasarkan sebagai '''Rebagen'''), dan Rusia (dipasarkan sebagai '''Rebagit)'''.<ref>{{Cite web|url=http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=bb32bbf8-84de-45c9-8ccf-df0789843d66&t=|title=Russian State Register of Medicines. Registration Sertificate: Rebagit (rebamipide) Film-Coated Tablets|language=Russian|access-date=10 June 2017}}</ref> Obat ini tidak disetujui oleh Badan Pengawasan Obat dan Makanan Amerika Serikat ([[Badan Pengawas Obat dan Makanan Amerika Serikat|US Food and Drug Administration]]).

Peneilitian telah menunjukkan bahwa rebamipiderebamipid dapat melawan efek merusak [[Obat antiinflamasi nonsteroid|NSAID]] pada mukosa [[Sistem pencernaan|saluran pencernaan]],<ref>{{Cite journal|last=Zhang|first=Shaoheng|last2=Qing|first2=Qing|last3=Bai|first3=Yang|last4=Mao|first4=Hua|last5=Zhu|first5=Wei|last6=Chen|first6=Qikui|last7=Zhang|first7=Yali|last8=Chen|first8=Ye|date=2013|title=Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis|url=https://www.ncbi.nlm.nih.gov/pubmed/23456504|journal=Digestive Diseases and Sciences|volume=58|issue=7|pages=1991–2000|doi=10.1007/s10620-013-2606-0|issn=1573-2568|pmid=23456504}}</ref> dan baru-baru ini pada usus halus, tetapi tidak untuk kerusakan lambung yang diinduksi [[naproksen]].<ref>{{Cite journal|last=Gagliano-Jucá|first=Thiago|last2=Moreno|first2=Ronilson A.|last3=Zaminelli|first3=Tiago|last4=Napolitano|first4=Mauro|last5=Magalhães|first5=Antônio Frederico N.|last6=Carvalhaes|first6=Aloísio|last7=Trevisan|first7=Miriam S.|last8=Wallace|first8=John L.|last9=De Nucci|first9=Gilberto|date=2016-06-04|title=Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial|url=https://www.ncbi.nlm.nih.gov/pubmed/27259970|journal=BMC gastroenterology|volume=16|issue=1|pages=58|doi=10.1186/s12876-016-0472-x|issn=1471-230X|pmc=PMC4893238|pmid=27259970}}</ref> Obat juga telah dipelajari untuk pengobatan [[Penyakit Behçet|penyakit Behçet]].<ref>{{Cite journal|year=2003|title=Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study|journal=Drugs in R&D|volume=4|issue=1|pages=19–28|doi=10.2165/00126839-200304010-00002|pmid=12568631}}</ref> Itu terbukti berhasil mengobati pouchitis dalam studi N-tunggal setelah terapi lini pertama untuk kondisi tersebut tidak berhasil.<ref>http://www.wjgnet.com/1007-9327/12/656.pdf

{{Webarchive}}</ref> Beberapa penelitian telah menunjukkan efektivitas pada presbyacusis ([[Ketulian|gangguan pendengaran]] terkait usia). <ref>{{Cite journal|last=Takumida|first=Masaya|last2=Anniko|first2=Matti|date=2005|title=Radical scavengers: a remedy for presbyacusis. A pilot study|url=https://www.ncbi.nlm.nih.gov/pubmed/16303676|journal=Acta Oto-Laryngologica|volume=125|issue=12|pages=1290–1295|doi=10.1080/00016480510037032|issn=0001-6489|pmid=16303676}}</ref>

Obat juga telah terbukti mengurangi tanda dan gejala [[Xerophtalmia|mata kering]] (xerophtalmia) dalam uji coba terkontrol secara acak meskipun ini belum tersedia secara klinis.<ref>{{Cite journal|last=Kinoshita|first=S.|last2=K. Oshiden|last3=S. Awamura|last4=H. Suzuki|last5=N. Nakamichi|year=2013|title=A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye|journal=Ophthalmology|volume=120|issue=6|pages=1158–65|doi=10.1016/j.ophtha.2012.12.022|pmid=23490326}}</ref>

[[Kategori:Asam aminoBenzamida]]